Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
Public ClinicalTrials.gov record NCT05267106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal.
Study identification
- NCT ID
- NCT05267106
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2022 (Actual)
- Primary completion
- Dec 17, 2024 (Actual)
- Completion
- Dec 17, 2024 (Actual)
- Last update posted
- Dec 30, 2025
2022 – 2024
United States locations
- U.S. sites
- 32
- U.S. states
- 15
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valkyrie Clinical Trials | Beverly Hills | California | 90211 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Providence Medical Foundation | Fullerton | California | 92835 | — |
| Usc Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Stanford Neuroscience Health Center | Sacramento | California | 94304 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| Providence St Joseph Hospital Orange Center For Cancer Prevention and Treatment | Santa Monica | California | 90404 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510-3220 | — |
| Baptist Md Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Orlando Health Cancer Institute Downtown Orlando | Orlando | Florida | 32806 | — |
| H. Lee Moffitt Cancer Center and Research Institute Hospital | Tampa | Florida | 33612 | — |
| University of Illinois Hospital & Health Sciences System | Chicago | Illinois | 60612 | — |
| University of Iowa Hospital and Clinics | Iowa City | Iowa | 52242 | — |
| University Medical Center New Orleans | New Orleans | Louisiana | 70112 | — |
| University of Minnesota Health Clinics and Surgery Center | Minneapolis | Minnesota | 55455 | — |
| Northwell Health | Lake Success | New York | 11042 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| East Carolina University | Greenville | North Carolina | 27834 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| UC Health At Cincinnati Va Medical Center | Cincinnati | Ohio | 45229 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| University of Pennsylvania Hospital | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Medical Center Health System | Pittsburgh | Pennsylvania | 15232 | — |
| Tennessee Oncology | Chattanooga | Tennessee | 37403 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05267106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 30, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05267106 live on ClinicalTrials.gov.